Just one large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading. Precision medicine company Tempus AI (TEM) priced at the high end to raise $411 million at a $6.4 billion market cap....read more
Telix Pharmaceuticals, a commercial-stage Australian biotech developing therapeutic and diagnostic radiopharmaceuticals, has decided not to move forward with its US IPO, citing market conditions. It had filed to raise $202 million by offering 17 million ADSs at...read more
Two sizable IPOs are scheduled for the week ahead. Precision medicine company Tempus AI (TEM) plans to raise $400 million at a $6.2 billion market cap. The company provides its Tempus Platform, which includes proprietary software and data...read more
Telix Pharmaceuticals, a commercial-stage Australian biotech developing therapeutic and diagnostic radiopharmaceuticals, announced terms for its IPO on Wednesday. The North Melbourne, Australia-based company plans to raise $202 million by offering 17 million...read more
US IPO Weekly Recap: Precision medicine IPO Tempus AI posts a modest gain in its debut
Just one large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading. Precision medicine company Tempus AI (TEM) priced at the high end to raise $411 million at a $6.4 billion market cap....read more
Australian radiopharmaceutical biotech Telix Pharmaceuticals pulls $202 million US IPO
Telix Pharmaceuticals, a commercial-stage Australian biotech developing therapeutic and diagnostic radiopharmaceuticals, has decided not to move forward with its US IPO, citing market conditions. It had filed to raise $202 million by offering 17 million ADSs at...read more
US IPO Week Ahead: Summer IPO market continues with precision medicine and radiopharmaceuticals
Two sizable IPOs are scheduled for the week ahead. Precision medicine company Tempus AI (TEM) plans to raise $400 million at a $6.2 billion market cap. The company provides its Tempus Platform, which includes proprietary software and data...read more
Australian radiopharmaceutical biotech Telix Pharmaceuticals sets terms for $202 million US IPO
Telix Pharmaceuticals, a commercial-stage Australian biotech developing therapeutic and diagnostic radiopharmaceuticals, announced terms for its IPO on Wednesday. The North Melbourne, Australia-based company plans to raise $202 million by offering 17 million...read more